Herbal medicinal product: Polypodii rhizoma, Polypodium vulgare L., C: ongoing call for scientific data
EMA Management Board elects new chair
Agenda of the HMPC meeting 17-19 March 2025
Opinion/decision on a Paediatric investigation plan (PIP): RoActemra, tocilizumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Infections and infestations, PIP number: P/0028/2024
Orphan designation: Trehalose Treatment of neuronal ceroid lipofuscinosis, 19/10/2020 Withdrawn
Orphan designation: Humanised IgG4 monoclonal antibody against C1q Treatment of Guillain-Barré syndrome, 10/02/2025 Positive
Orphan designation: sutimlimab Treatment of autoimmune haemolytic anaemia, 11/02/2025 Positive
Orphan designation: Upifitamab rilsodotin Treatment of ovarian cancer, 09/12/2022 Withdrawn
Orphan designation: pelabresib monohydrate Treatment of myelofibrosis, 17/02/2025 Positive
Orphan designation: Adeno-associated viral vector serotype rh10 containing the human cholesterol 24-hydroxylase gene Treatment of Huntington’s disease, 01/04/2019 Withdrawn